Raltegravir potassium is a human immunodeficiency virus integrase strand transfer inhibitor. The drug is soluble in water and slightly soluble in ethanol and methanol as well. The pharmaceutically acceptable salt has been approved for the treatment of HIV-1. The multinational pharmaceutical, Merck has signed an agreement with MPP (Medicines Patent Pool) to license its intellectual property[…]
New Raltegravir Potassium Merck Agreement Proves to be a Major Improvement Over the Status Quo
Anti-Retroviral / Anti-HIV, Drug Research & Development API, Patent Expiration 2023 Tags: AIDSHIV Dec 21, 2015
Dolutegravir Approved by the FDA as an Effectual Integrase Inhibitor
Anti-Retroviral / Anti-HIV Tags: AIDSHIV infectionHIV virus Aug 26, 2013
On August 12, 2013 Viiv Healthcare proudly announced the FDA approval of the integrase inhibitor, Dolutegravir to combat the HIV virus. Known as the brand name Tivicay, Dolutegravir is typically used in combination with other antiretroviral medications to treat patients with AIDS, ages twelve and older. With many patients living longer while being infected with[…]
Etravirine Remains a Formidable Treatment for AIDS
Anti-Retroviral / Anti-HIV, Antiviral, Drug Research & Development API, FDA Approved 2012, Patent Expiration 2019 Tags: AIDSHIV virus Jul 01, 2013
As a successful nonnucleoside reverse transcriptase inhibitor, Etravirine, CAS number 269055-15-4 is also known as the brand name Intelence. With the patent for Intelence set to expire for Janssen on November 5, 2019, additional research and development offering generic formulations of this effectual treatment for AIDS is sure to proliferate. Last year Etravirine was approved[…]
Can Ritonavir Boosted Fosamprenavir Lead to a Cure for AIDS?
Anti-Retroviral / Anti-HIV, Drug Research & Development API, Patent Expiration 2017 Tags: AIDSHIV virusNorvirRitonavir Mar 07, 2013
The recent headlines proclaiming a cure for a Mississippi baby who had been exposed to the HIV virus which causes AIDS have captivated the world. This child was born to an HIV positive mother who had not received any prenatal care to reduce the transmission of the virus. Dr. Hannah Gay, who treated the baby,[…]
Life Extending Enfuvirtide Looks to Become a Successful Generic
Anti-Retroviral / Anti-HIV, Patent Expiration 2013, Patent Expiration 2015 Tags: AIDSHIVHIV infectionRitonavir Jun 27, 2012
In June of 1981 the first known cases of AIDS in the United States were reported. Currently there are over 1.7 million people in the United States infected with HIV-1, the virus which causes AIDS, and over more then 600,000 Americans have already died from this ultimately fatal disease. With 1.2 million Americans estimated to[…]
Monotherapy with Darunavir is Where the "MONET" is
Anti-Retroviral / Anti-HIV, Drug Research & Development API Tags: AIDSDarunavir EthanolateHIVHIV virusRitonavir Sep 02, 2011
AIDS is a global pandemic whose cure has eluded scientists and doctors for more than 2 decades. Acquired immunodeficiency syndrome (AIDS) is caused by the Human Immunodeficiency Virus (HIV) which progressively undermines the strength of the immune system until such a time that the body becomes incapable of fighting off infections and vulnerable to opportunistic[…]
Plerixafor – Primary Usage, Stem Cells, and Availability for R&D Purposes
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API Tags: AIDSHIV Jan 19, 2011
Plerixafor is a new compound that can be used as an effective drug to cure cancer patients. This drug is an immunostimulant and is used to increase hematopoietic stem cells in patients suffering from cancer. The stem cells are then transplanted into the patients. Initially, this drug was developed to help HIV patients because it[…]
